Need Help?

Intellance-2: omics data on recurrent glioblastoma patients participating in the Intellance-2 clinical trial, prior to treatment.

This study contains omics data from patients from the Intellance-2 clinical trial, in which effectiveness of ABT414 in EGFR amplified recurrent glioblastoma patients was tested. Patients were randomly assigned to one of three arms: (1) standard of care treatement (TMZ or CCNU), (2) Only ABT414 and (3) ABT414 + (TMZ|CCNU)

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001007943 Illumina NovaSeq 6000 224
EGAD00001007944 NextSeq 500 222
EGAD00001007945 NextSeq 500 216
Publications Citations
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Neurooncol Adv 2: 2020 vdz051
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Neuro Oncol 24: 2022 429-441